In vitro-induced cell-mediated immune deviation to encephalitogenic antigens

Area of Science:

• Immunology
• Neuroscience
• Ophthalmology

Background:

• Anterior Chamber Associated Immune Deviation (ACAID) is an immune-suppressive mechanism induced by ocular antigen injection.
• Transforming growth factor beta 2 (TGFβ2) in aqueous humor plays a key role in ACAID by influencing ocular antigen-presenting cells (APCs).
• ACAID promotes the generation of antigen-specific T regulatory cells, crucial for immune tolerance.

Purpose of the Study:

• To investigate if in vitro-generated ACAID APCs or B cells specific to encephalitogenic antigens Myelin oligodendrocyte glycoprotein (MOG) and Myelin basic protein (MBP) can induce peripheral tolerance.
• To evaluate the suppression of MOG35-55-specific and MBP-specific inflammatory responses in recipient mice.

Main Methods:

• Induction of ACAID in vitro using MOG35-55 and MBP antigens.
• Intravenous injection of in vitro-generated ACAID APCs, ACAID B cells, or ACAID T regulatory cells into recipient BALB/c mice.
• Assessment of antigen-specific immune suppression using delayed-type hypersensitivity (DTH) assays and Local Adoptive Transfer (LAT) assays.

Main Results:

• Intravenous administration of MOG35-55-specific/MBP-specific ACAID APCs, ACAID B cells, and ACAID T regulatory cells successfully induced antigen-specific tolerance.
• The induced immune deviation was cell-mediated and specific to the encephalitogenic antigens MOG35-55/MBP.
• Delayed-type hypersensitivity and Local Adoptive Transfer assays confirmed the suppression of inflammatory responses.

Conclusions:

• In vitro generation of ACAID-inducing cells provides a method for establishing antigen-specific peripheral tolerance.
• This approach holds promise for developing novel cell-based therapies for autoimmune diseases such as Multiple Sclerosis and Schizophrenia.
• ACAID represents a valuable immunomodulatory strategy for treating diseases associated with specific antigen-driven immune responses.